# Vanda Pharmaceuticals share price today (Vanda Pharmaceuticals Inc., VNDA)

> Vanda Pharmaceuticals Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VNDA · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/vnda

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.88 (−11.8% in a year)
- Revenue (Jun 2026): $50.5 M (−3.9% on a year ago)
- Profit (Jun 2026), incl. one-off: −$62.5 M (one-off item, see below)
- Operating margin: −126.3% (−53.1 points on a year ago)
- ROE: −67%, FY25
- ROIC: −230.6%, against a 7.6% cost of capital: −238.2 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Vanda Pharmaceuticals share price today? Vanda Pharmaceuticals Inc.'s share price was $3.88 at the close on 4 November 2026. That is 37.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $9, and at that close it sat 2% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 30 weeks running. Over the last 1 year the share price moved −18% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 10 April 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Vanda Pharmaceuticals pay? Vanda Pharmaceuticals Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Vanda Pharmaceuticals on? Vanda Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Vanda Pharmaceuticals profitable? Vanda Pharmaceuticals Inc. posted a net loss of $62.5 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $220 M. That loss is 123.7% of the quarter's revenue. The same quarter a year earlier lost $27.2 M. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −$62.5 M it is bigger than the quarter's whole revenue of $50.5 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −126.3% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Vanda Pharmaceuticals make, and is it growing? Vanda Pharmaceuticals Inc. reported $50.5 M of revenue in the Jun 2026 quarter, −3.9% on the same quarter a year earlier. Over 4 years it has grown −5.3% a year on average. The last full year, FY25, came in at $216 M. The last four reported quarters add to $216 M. FY25 revenue was $216 M, +8.7% on the year before. Recent pace: the last four quarters grew +6.3% on average, against −5.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.0%, against +8.9% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Vanda Pharmaceuticals keep? Vanda Pharmaceuticals Inc.'s operating margin was −126.3% in the Jun 2026 quarter, 53.1 percentage points lower than the same quarter a year ago. Across 5 years it has been between −70.0% and 15.7%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −53.1 percentage points on the year while gross margin changed −1.8 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Vanda Pharmaceuticals' profit turning into cash? Over the last 3 years, 260% of Vanda Pharmaceuticals Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 its operations used $109 M of cash, against −$220 M of profit. After $998 K of spending on assets, free cash was −$110 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Vanda Pharmaceuticals' cash go? Vanda Pharmaceuticals Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $107 M on assets over the last 3 years. Averaged over those years that is 16.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $107 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Vanda Pharmaceuticals' P/E ratio, and how does it compare with its own history? Vanda Pharmaceuticals Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Vanda Pharmaceuticals Inc. at 1.1× its FY25 revenue of $216 M. The P/E comes back here once profit turns positive. ## Is the Vanda Pharmaceuticals business getting better or worse? Vanda Pharmaceuticals Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Vanda Pharmaceuticals earn on its capital? Vanda Pharmaceuticals Inc. earned a ROE of −67% in FY25. Its return on capital used (ROIC) is 238.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −102.0% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −102.0% net margin × 0.44× asset turnover × 1.49× leverage (assets divided by equity) ≈ −66.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −230.6% − 7.6% = −238.2 percentage points. The 7.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −230.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −119.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Vanda Pharmaceuticals have too much debt? Vanda Pharmaceuticals Inc. has total debt of $22.8 M against shareholder equity of $220 M as of Jun 2026, so its debt is 0.10× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.04 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Vanda Pharmaceuticals shareholding pattern? 17.8% of Vanda Pharmaceuticals Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Vanda Pharmaceuticals from balance-sheet trouble? For Vanda Pharmaceuticals Inc., the Z-score is −1.38. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.38 is inside the danger zone, so the balance sheet is a real risk. ## How does Vanda Pharmaceuticals rank in its industry? There is no score against its industry: Vanda Pharmaceuticals Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Vanda Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Vanda Pharmaceuticals in size? Vanda Pharmaceuticals is the 186th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Immuneering Corporation, Abeona Therapeutics Inc. and Camp4 Therapeutics Corporation. Just below it: AC Immune SA, Evommune, Inc. and InflaRx N.V. ### Biotechnology companies close in size

1. [Immuneering Corporation](https://www.sectoralpha.in/us/stocks/imrx) $244 million
2. [Abeona Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/abeo) $241 million
3. [Camp4 Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/camp) $235 million
4. Vanda Pharmaceuticals Inc. $235 million
5. [AC Immune SA](https://www.sectoralpha.in/us/stocks/aciu) $228 million
6. [Evommune, Inc.](https://www.sectoralpha.in/us/stocks/evmn) $219 million
7. [InflaRx N.V.](https://www.sectoralpha.in/us/stocks/ifrx) $218 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Citizens Community Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/czwi) $228 million · Banks - Regional
2. [AstroNova, Inc.](https://www.sectoralpha.in/us/stocks/alot) $227 million · Computer Hardware
3. Vanda Pharmaceuticals Inc. $227 million
4. [Kolibri Global Energy Inc.](https://www.sectoralpha.in/us/stocks/kgei) $226 million · Oil & Gas Exploration & Production
5. [Serve Robotics Inc.](https://www.sectoralpha.in/us/stocks/serv) $226 million · Specialty Industrial Machinery

## What else do people ask about Vanda Pharmaceuticals? ### What were Vanda Pharmaceuticals's latest quarterly results? Vanda Pharmaceuticals Inc. reported revenue of $50.5 M and a net loss of $62.5 M for the Jun 2026 quarter. Earnings per share were −$1.04. The operating margin was −126.3%, 53.1 percentage points lower than a year earlier (as of 4 November 2026). ### What is Vanda Pharmaceuticals's market cap? Vanda Pharmaceuticals Inc.'s market capitalisation is $235 M at a stock price of $3.88. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Vanda Pharmaceuticals performing? Vanda Pharmaceuticals Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 30 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Vanda Pharmaceuticals's stock price go up? This page does not forecast Vanda Pharmaceuticals Inc.'s stock price. What it shows instead: the stock price is $3.88. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does Vanda Pharmaceuticals have too much debt? No, Vanda Pharmaceuticals Inc. has little debt: its debt is 0.11× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Vanda Pharmaceuticals in its business cycle? Vanda Pharmaceuticals Inc.'s FY25 operating margin was −70.0%, against a 5-year range of −70.0% to 15.7%: the low end of its own range, which is often where recoveries start. The latest quarter was −126.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Vanda Pharmaceuticals story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Vanda Pharmaceuticals a stock worth studying right now? What the numbers show: Vanda Pharmaceuticals Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.